Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report

Strippoli,Sabino; Traversa,Michele; Cramarossa,Antonio; Popescu,Ondina; Lorusso,Vito; Guida,Michele

doi:10.3892/ol.2015.3111

Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report

Authors:
- Sabino Strippoli
- Michele Traversa
- Antonio Cramarossa
- Ondina Popescu
- Vito Lorusso
- Michele Guida
View Affiliations

Affiliations: Department of Medical Oncology, National Cancer Research Centre ‘Giovanni Paolo II’, Bari 70124, Italy, Department of Radiology, National Cancer Research Centre ‘Giovanni Paolo II’, Bari 70124, Italy, Histopathology Unit, National Cancer Research Centre ‘Giovanni Paolo II’, Bari 70124, Italy
Published online on: April 14, 2015 https://doi.org/10.3892/ol.2015.3111
Pages: 2567-2571

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Extraskeletal osteosarcomas (EOSs) are rare variants of primary osteosarcoma of the bone, and are defined as sarcomas located in the soft tissues and characterized by osteoid production. EOS exhibits distinctive demographic, imaging and prognostic features compared with osteosarcoma of bone origin. The available data are contradictory with regard to the use of chemotherapy regimens in the management of EOS. The present study describes a case of EOS that progressed following two lines of therapy oriented to soft‑tissue and bone sarcoma histology, respectively. As a gemcitabine‑docetaxel combination schedule has demonstrated synergistic activity against bone and soft‑tissue sarcoma histologies, this chemotherapy regimen was selected as salvage therapy. The treatment was well‑tolerated and induced a long lasting partial response for ~14 months. To the best of our knowledge, this is the first report involving the clinical use of this combination regimen for the treatment of EOS. Furthermore, as demonstrated in this report, EOS may maintain relative chemosensitivity, indicating the potential to control advanced disease in the long term and to plan subsequent chemotherapy regimens.

View Figures

View References

1	McCarter MD, Lewis JJ, Antonescu CR and Brennan MF: Extraskeletal osteosarcoma: Analysis of outcome of a rare neoplasm. Sarcoma. 4:119–123. 2000. View Article : Google Scholar : PubMed/NCBI
2	Lidang Jensen M, Schumacher B, Myhre Jensen O, Steen Nielsen O and Keller J: Extraskeletal osteosarcomas: A clinicopathologic study of 25 cases. Am J Surg Pathol. 22:588–594. 1998. View Article : Google Scholar : PubMed/NCBI
3	Sordillo PP, Hajdu SI, Magill GB and Golbey RB: Extraosseous osteogenic sarcoma. A review of 48 patients. Cancer. 51:727–734. 1983. View Article : Google Scholar : PubMed/NCBI
4	Bane BL, Evans HL, Ro JY, Carrasco CH, Grignon DJ, Benjamin RS and Ayala AG: Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer. 65:2762–2770. 1990. View Article : Google Scholar : PubMed/NCBI
5	Allan CJ and Soule EH: Osteogenic sarcoma of the somatic soft tissues. Clinicopathologic study of 26 cases and review of literature. Cancer. 27:1121–1133. 1971. View Article : Google Scholar : PubMed/NCBI
6	Goldstein-Jackson SY, Gosheger G, Delling G, Berdel WE, Exner GU, Jundt G, Machatschek JN, Zoubek A, Jurgens H and Bielack SS: Cooperative Osteosarcoma Study Group COSS: Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. J Cancer Res Clin Oncol. 131:520–526. 2005. View Article : Google Scholar : PubMed/NCBI
7	Torigoe T, Yazawa Y, Takagi T, Terakado A and Kurosawa H: Extraskeletal osteosarcoma in Japan: Multiinstitutional study of 20 patients from the Japanese Musculoskeletal Oncology Group. J Orthop Sci. 12:424–429. 2007. View Article : Google Scholar : PubMed/NCBI
8	Casali PG: Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. Ann Oncol. 23:x167–x169. 2012. View Article : Google Scholar : PubMed/NCBI
9	Patel SR and Benjamin RS: Primary extraskeletal osteosarcoma - experience with chemotherapy. J Natl Cancer Inst. 87:1331–1333. 1995. View Article : Google Scholar : PubMed/NCBI
10	Ahmad SA, Patel SR, Ballo MT, et al: Extraosseous osteosarcoma: Response to treatment and long-term outcome. J Clin Oncol. 20:521–527. 2002. View Article : Google Scholar : PubMed/NCBI
11	Bay JO, Ray-Coquard I, Fayette J, et al: Groupe Sarcome Francais: Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer. 119:706–711. 2006. View Article : Google Scholar : PubMed/NCBI
12	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
13	Maki RG, Wathen JK, Patel SR, et al: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 25:2755–2763. 2007. View Article : Google Scholar : PubMed/NCBI
14	Leu KM, Ostruszka LJ, Shewach D, et al: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 22:1706–1712. 2004. View Article : Google Scholar : PubMed/NCBI
15	Rapkin L, Qayed M, Brill P, Martin M, Clark D, George BA, Olson TA, Wasilewski-Masker K, Alazraki A and Katzenstein HM: Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer. 59:854–858. 2012. View Article : Google Scholar : PubMed/NCBI
16	Pautier P, Floquet A, Penel N, et al: Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: A Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 17:1213–1220. 2012. View Article : Google Scholar : PubMed/NCBI
17	Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W and Daw NC: Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 113:419–425. 2008. View Article : Google Scholar : PubMed/NCBI
18	Frustaci S, Gherlinzoni F, De Paoli A, et al: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J Clin Oncol. 19:1238–1247. 2001.PubMed/NCBI
19	Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R and Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol. 20:2824–2831. 2002. View Article : Google Scholar : PubMed/NCBI
20	Qi WX, He AN, Tang LN, Shen Z, Lin F and Yao Y: Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: A retrospective study of 18 patients. Jpn J Clin Oncol. 42:427–431. 2012. View Article : Google Scholar : PubMed/NCBI
21	He A, Qi W, Huang Y, Sun Y, Shen Z, Zhao H, Yang Y and Yao Y: Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: A single institution experience. Int J Clin Oncol. 18:498–505. 2013. View Article : Google Scholar : PubMed/NCBI
22	Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D, Reinke D, Chugh R, Benjamin RS and Helman LJ: Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 17:3212012. View Article : Google Scholar : PubMed/NCBI
23	Wilson H: Extraskeletal ossifying tumors. Ann Surg. 113:95–112. 1941. View Article : Google Scholar : PubMed/NCBI
24	Gosiengfiao Y, Reichek J, Woodman J, Ben-Ami T and Walterhouse D: Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital. J Pediatr Hematol Oncol. 34:e63–e65. 2012. View Article : Google Scholar : PubMed/NCBI
25	Gronchi A, Verderio P, De Paoli A, et al: Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. Ann Oncol. 24:817–823. 2013. View Article : Google Scholar : PubMed/NCBI
26	Souhami RL, Craft AW, Van der Eijken JW, et al: Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet. 350:911–917. 1997. View Article : Google Scholar : PubMed/NCBI